Literature DB >> 29726897

Incidence and Risk Factor Analysis of Thromboembolic Events in East Asian Patients With Inflammatory Bowel Disease, a Multinational Collaborative Study.

Meng-Tzu Weng1,2,3, Sang Hyoung Park4, Katsuyoshi Matsuoka5, Chien-Chih Tung1, Jae Yong Lee4, Chin-Hao Chang6, Suk-Kyun Yang4, Mamoru Watanabe5, Jau-Min Wong1, Shu-Chen Wei1.   

Abstract

Background: Inflammatory bowel disease (IBD) increases the risk of venous thromboembolism (VTE) events. However, the incidence and necessity of prophylaxis for VTE in Asian IBD patients is unknown. We examined the incidence of VTE in East Asian IBD patients and analyze the possible risk factors.
Methods: We conducted a multinational retrospective study of 2562 hospitalized IBD patients from 2010 to 2015. Moreover, a nationwide cohort study from 2001 to 2013 from the Taiwan National Health Insurance Research Database (NHIRD) was conducted to analyze the incidence rate of VTE in IBD and non-IBD patients.
Results: In the hospitalized cohort, 24 IBD patients [17 ulcerative colitis (UC) and 7 Crohn's disease (CD)] received a VTE diagnosis (0.9%). These patients had a higher proportion of extensive UC (P = 0.04), penetrating-type CD (P < 0.01), and bowel operation history (P = 0.01). VTE was associated with low hemoglobin (P < 0.01), low platelet (P < 0.01), and low albumin (P < 0.01) levels. For the nation-wide cohort study, 3178 IBD patients and 31,780 age- and sex-matched non-IBD patients were analyzed. The average incidence rate was 1.15 per 1000 person-years in the IBD cohort and 0.51 in the non-IBD cohort. The relative risk was 2.27 (95% CI, 1.99-2.60). Conclusions: East Asian IBD patients carry a 2-fold increased risk of VTE than the general population. The incidence of VTE in the East Asian IBD patients is still lower than that in Western countries. Therefore, close monitoring rather than routine prophylaxis of VTE in East Asian IBD patients is recommended.

Entities:  

Mesh:

Year:  2018        PMID: 29726897     DOI: 10.1093/ibd/izy058

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  16 in total

1.  International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Authors:  Pablo A Olivera; Stephane Zuily; Paulo G Kotze; Veronique Regnault; Sameer Al Awadhi; Peter Bossuyt; Richard B Gearry; Subrata Ghosh; Taku Kobayashi; Patrick Lacolley; Edouard Louis; Fernando Magro; Siew C Ng; Alfredo Papa; Tim Raine; Fabio V Teixeira; David T Rubin; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-27       Impact factor: 46.802

2.  Inflammatory bowel disease and thromboembolic events: a c'lot to learn.

Authors:  Ana Catarina Carvalho; Juliana Pinho; Eugénia Cancela; Hugo Marcelo Vieira; Américo Silva; Paula Ministro
Journal:  Therap Adv Gastroenterol       Date:  2022-05-25       Impact factor: 4.802

3.  Is the Risk for Venous Thromboembolism in East Asian Patients with Inflammatory Bowel Disease Comparable to That in Western Patients?

Authors:  Sung Wook Hwang
Journal:  Gut Liver       Date:  2022-07-15       Impact factor: 4.321

4.  Real-World Insurance Claims Analysis of Venous Thromboembolism in Japanese Patients with Inflammatory Bowel Disease.

Authors:  Mikihiro Fujiya; Tsutomu Kawaguchi; Shoko Arai; Naoki Isogawa; Shintaro Hiro; Fumihiro Matsumoto; Satoshi Yamaguchi; Noritoshi Yoshii; Mashio Nakamura; Katsuyoshi Matsuoka
Journal:  Dig Dis Sci       Date:  2022-02-12       Impact factor: 3.487

5.  Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.

Authors:  David T Rubin; Irene Modesto; Séverine Vermeire; Silvio Danese; Siew C Ng; Kenneth K Kwok; Nana Koram; Thomas V Jones
Journal:  Aliment Pharmacol Ther       Date:  2021-10-09       Impact factor: 9.524

6.  Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.

Authors:  William J Sandborn; Julian Panés; Bruce E Sands; Walter Reinisch; Chinyu Su; Nervin Lawendy; Nana Koram; Haiyun Fan; Thomas V Jones; Irene Modesto; Daniel Quirk; Silvio Danese
Journal:  Aliment Pharmacol Ther       Date:  2019-10-09       Impact factor: 8.171

Review 7.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Kimberly Cheng; Adam S Faye
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

8.  Prevalence of Asymptomatic Venous Thromboembolism in Depressive Inpatients.

Authors:  Masahiro Takeshima; Hiroyasu Ishikawa; Yoshiaki Umeta; Mizuki Kudoh; Akise Umakoshi; Kazuhisa Yoshizawa; Yu Ito; Tomoko Hosoya; Ko Tsutsui; Hidenobu Ohta; Kazuo Mishima
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-26       Impact factor: 2.570

9.  Risk of venous thromboembolism in Asian patients with inflammatory bowel disease: a nationwide cohort study.

Authors:  Tae Jun Kim; Young-Ho Kim; Chan Mi Heo; Eun Ran Kim; Sung Noh Hong; Dong Kyung Chang; Mi Yang; Seonwoo Kim
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

10.  Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.

Authors:  Séverine Vermeire; Chinyu Su; Nervin Lawendy; Taku Kobayashi; William J Sandborn; David T Rubin; Irene Modesto; Sean Gardiner; Nicole Kulisek; Haiying Zhang; Wenjin Wang; Julian Panés
Journal:  J Crohns Colitis       Date:  2021-07-05       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.